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The lysis of cells by complement requires only the terminal components C5, C6,
C7, C8 andC9 and is initiated by the cleavage of C5 to C5b . Sequential addition
of C6, C7, C8, and C9 to C5b leads to the formation of the membrane attack com-
plex (MAC)' which, when inserted into the lipid bilayer, can form transmembrane
pores (1-5) . It is well known that when complement of one species is activated on
homologous erythrocytes, lysis is much less efficient than when it is activated on
other species of cell, and even among different heterologous cell species the lytic
efficiency may be very different . It has long been known that the basis of this vari-
able lytic efficiency is found, at least in part, at the C8 and/or C9 step (6-9) . More
recently, specific membrane proteins have been described that appear to protect cells
from homologous complement . The first of these to be described was the decay-
accelerating factor (DAF), amembrane protein of-70kD molecular mass (10) . This
protein interferes with the assembly of the C3 converting enzymes both of the clas-
sical and alternative pathway (10, 11) and therefore it has only indirect effects on
the cell lytic mechanism . Afurthermembrane protein that does restrict homologous
lysis, and that has been described both as the C8-binding protein (C8bp) (7, 12)
and as homologous restriction factor (HRF) (13), has also been isolated . It seems
likely that both these descriptions apply toasingle proteinof 65 kD molecularmass .
In addition, a 55/65-kD MAC-inhibiting protein (MIP) with the capacity to bind
C8 and C9 hasbeen identified both on humanerythrocytemembranesand in normal
human serum(14). Therelationship ofthis to HRF/C8bp is notyet clear. Both DAF
and HRF/C8bp are bound on cell membranes by a glycolipid anchor (15, 16) and
can be eluted from the cell membrane, at least in part, by phosphatidylinositol-specific
phospholipaseC. These proteins also have thecapacity when they are isolated from
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membranes to be reinserted into lipid bilayers, and when HRF/C8bp (12, 17) is in-
serted in this way into sheep erythrocytes, this limits their lysisby human complement.
A mAb (YTH 53.1), raised against a lymphocyte surface antigen, has been demon-
strated to potentiate lysis by homologous complement in a manner analogous to
that of antibodies against HRF/C8bp. At the 4th Leucocyte Workshop this anti-
body, together with antibody MEM-43 (18), was placed in a cluster designated CD59
(19). Here we describe the isolation both from urine and from red cell membranes
of the antigen recognized by YTH 53 .1. It is distinct from HRF/C8bp in having
a much smaller molecular mass (-20 kD), but appears to restrict homologous lysis
in an analogous way. The cDNA encoding this protein has been isolated using tran-
sient expression in COS cells (20); the deduced amino acid sequence is in full agree-
ment with the NH2-terminal sequence ofthe purified protein and shows homology
to murine LY-6 antigens. The functional data presented herein indicate that CD59
antigen is a novel lysis-restricting protein.
Materials and Methods
Antibodies andReagents.
￿
The mAbs YTH 53.1 (rat IgG2b), YTH 89.1 (rat IgG2b anti-red
cell glycophorin A), YTH 66.9 (rat IgM; CAMPATH-1), and YTH 3.2 (rat IgG2b CD7 ;
CAMPATH-2) were obtained from the fusion of a DA rat spleen with the myeloma line
Y3/Ag1.2.3 (21). The anti-blood group mAbs NBl/19.112.28 (mouse IgM anti-B) and
A15/3D3.92.1 (mouse anti-A) were the kind gift of Dr. E. Lennox, Celltech, Slough, U.K.
(22, 23). Polyclonal antiserum against MAC-inhibiting protein was the gift of M. J . Watts/
Department of Medical Biochemistry, University ofWalesCollege ofMedicine, Cardiff, UK.
Phosphatidylinositol-specific phospholipase C was the gift ofDr. S. Udenfriend, Roche Insti-
tute, (Nutley, NJ). The mAb Ell against CRl was the gift of Dr. N. Hogg (Imperial Cancer
Research Fund, Lincoln's Inn Fields, London).
Isolation ofIgGfrom Serum andAscites.
￿
IgG was prepared from serum or ascites by a method
based upon that of Steinbuch and Audran (24). Firstly, the majority of unwanted plasma
proteins were removed from the sample by precipitation with caprylic acid at a finalconcen-
tration of 5%. The pH ofthe sample was first adjusted to 5.0 with 3 M acetic acid, and the
caprylic acid was added dropwise during rapid stirring of the sample. After stirring for 30
min at room temperature, the protein precipitate was removed by centrifugation and IgG
was purified from the resulting supernatant by precipitation with 40% ammonium sulphate.
The precipitated IgG was dissolved in the minimum volume of distilled water and dialyzed
against PBS. IgG preparations were checked for purity by immunoelectrophoresis.
Preparation ofF(ab)2 Fragments.
￿
A crude Ig fraction was prepared from ascitic fluid ofYTH
53.1 by precipitation with 50% saturated ammonium sulphate. It was then dialyzed against
0.1 M sodium phosphate, pH 7.8, and adjusted to a protein concentration of 10 mg/ml. To
1 ml of this solution 0.3 mg of Staphylococcus aureus V8 protease was added, the mixture was
incubated at 37'C for 4 h (25), then 1 ml of saturated ammonium sulphate was added to
precipitate the F(ab')2 fragments from the digest. The precipitate was redissolved in 0.2 ml
of PBS and gel filtered on a column of Sepharose CL-6B (68 x 0.65 cm) equilibrated with
PBS containing 0.02 % sodium azide. Fractions were analyzed by SDS-PAGE and those con-
taining pure F(ab')2 fragments were pooled. No trace of intact heavy chain could be detected
in the digest or the purified fractions.
Immunofuorescence and Flow Cytometry.
￿
Cells were incubated with YTH 53.1 followed by
fluorescein-labeled goat anti-rat Ig as described previously (21). The cells were washed and
resuspended in PBS containing 1% BSA and fixed by the addition of formaldehyde to a final
concentration of 1%. The fluorescent cellswere later analyzed using a Cytofluorograf model
50-H (Ortho Diagnostic Systems Inc., Westwood, MA) as described (21).
Complement-mediated Cell Lysis.
￿
Cells were labeled with "Cr and washed with culture
medium (Iscove's modified Dulbeccds medium buffered with Hepes and containing 1% BSADAVIES ET AL.
￿
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as described before (21). Aliquots(50 pl) ofthe cell suspension were added to microtiter plates
containing50pl ofantibody diluted in medium. After incubation for 10 min at room temper-
ature, 100 jz1 ofcomplement(autologous or AB serum diluted in medium) was added. When
two antibodies were used (50 pl each) then 50 11 of double-strength complement was used
so that the final volume was the same. The mixture was incubated for 45 min at 37°C, cen-
trifuged at 100 g for 2 min and 100 Al of the supernatants was collected for measurement
of released radioactivity. Specific release was calculated in the usual way as a fraction of the
difference between a positive control (resuspended cells) and a negative control (no antibody).
ReactiveLysis.
￿
Reactive lysis ofhuman or guinea pig erythrocytes was carried out in agarose
plates as described by Harrison and Lachmann (26). Erythrocytes were washed three times
in PBS and resuspended to a final concentration of0.5% in agarose made to 1% in PBS/10
mM EDTA. Activated C56 was prepared from acute-phase serum as described by the above
(26) and normal human serum or rabbit serum were used as a source of C7-9. Reagents
were added to 3-mm diameter wells cut in the agarose N3 mm apart, and the plates were
incubated at room temperature untillines oflysis developed between the wells (time specified
in the text).
Affinity Purification of CD59 Antigenfrom HumanErythrocyte Membranes.
￿
Four units of blood
(group A) were obtained from the Regional Blood Transfusion Centre, Cambridge. Approxi-
mately 1 liter of packed red cells that had been washed six times in PBS110 mM azide were
lysed in 10 liters of 5 mM sodium phosphate/l mM EDTA/5 mM benzamidine/5 mM iodo-
acetamide, pH 7.8, by gentle stirring at 4°C. The erythrocyte ghosts were washed extensively
in lysis buffer using a Pellicon cassette system (cassette PTGC 000 05; mol wt cutoff 1,000,000;
Millipore [UK] Ltd., Watford, U.K.) and finally solubilized in lysisbuffer containing 150 mM
NaCl and 1% NP40. Insoluble material was removed by centrifugation and the supernatant
was dialyzed against lysis buffer containing 150 mM NaCl and 0.2% NP-40. An affinity column
was prepared by coupling 20 mg of YTH 53.1 IgG to 4 ml of CNBr-activated Sepharose
CL-4B. To remove material that might adhere nonspecifically to the column of antibody-
coupled Sepharose, two precolumns bearing nonimmune mouse IgG and Ell monoclonal
IgG against CRl were prepared. All columns were washed in PBS/10 mM azide and elution
buffer before equilibration in lysis buffer containing 150 mM NaCl and 0.2% NP-40. The
solubilized ghost extract was passed over the two precolumns, then once over the YTH 53.1/
Sepharose column before beingallowed to recirculate overnight. After washing in PBS110 mM
azide/0.2 % NP-40 and 1 M NaCl/0.2% NP-40, the column was eluted with 0.1 M acetic
acid, pH 3.0/0.2 'Yo NP-40. 0.5-ml fractions were collected into tubes containing 50 pl N-ethyl-
morpholine. The final yield of protein was -700 p.g.
Affnity Purification of CD59 Antigenfrom Human Urine.
￿
The same affinity column that was
used to purify CD59 antigen from human erythrocyte membranes was used to extract the
protein from human urine. Urine was collected from normal donors in 8-liter batches over
a period 5 d, during which time it was either stored at 4°C for immediate use, or frozen
at -30°C for up to 3 wk, then filtered and concentrated to 300 ml using a Pellicon cassette
system (cassette PSVP 000 05, molecular weight cutoff 10,000; Millipore (UK) Ltd.). Condi-
tions for running and eluting the column were as before. Several preparations were made
from different batches of urine, and the yield ranged from 20 to 100 kg per liter.
SDS-PAGE.
￿
SDS-PAGE was performed using the buffer system ofLaemmli (27). Protein
samples were prepared for electrophoresis under both reducing and nonreducing conditions,
and gels were stained with Coomassie Brilliant Blue or silver nitrate. Molecular weight stan-
dards were purchased from BDH, Poole, U.K.
Raising Alyclonal Antiserum.
￿
A rabbit polyclonal antiserum was raised against the urine
form of CD59 antigen. For the first injection, 80 kg of protein was emulsified in CFA. A
second injection of 80 p.g with Pertussis was given 2 wk later, followed by booster injections
containing 50 hg alum-precipitated protein.
Protein Sequence Analysis.
￿
NH2-terminal sequence analysis using 100-300-pmol samples
ofprotein was carried out by Dr. L. Packman at the Protein Sequencing Facility ofthe Depart-
ment of Biochemistry, University of Cambridge, usingan Applied Biosystems (Foster City,
CA) gas phase sequencer. One sample of the membrane-derived protein was reduced and
alkylated before sequencing.640
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Protein Reduction andAlkylation.
￿
0.5 mg of membrane-derived CD59 antigen in 0.5 ml Tris-
HCl, pH 8.2, was reduced and alkylated usingthe following procedure. Urea at a final con-
centration of 9.6 M and dithiothreitol at a final concentration of 10 mM were added, and
the reaction mixture was flushed with nitrogen before incubation in a sealed container for
20 min at room temperature. 0.1 ml of 0.2 M iodoacetic acid adjusted to pH 8.0 was then
added, the container was flushed again with nitrogen and resealed, then left again at room
temperature for 1 h in the dark. The reaction was terminated by the addition of two drops
of 2-ME, and the sample was dialyzed extensively against distilled deionized water.
Construction ofcDNA Libraries.
￿
RNA from an HTLV I-positive adult T cell leukemia (YT)
was the gift ofTadasuki Taniguchi, Osaka Medical School, Japan, to Brian Seed. cDNA libraries
were made as previously described (28) by a method based upon that of Gubler and Hoffman
(29). The libraries were constructed in the vector CDM8 (30) and the ligated DNA was trans-
formed into Escherichia coli MC1061/p3. Libraries were constructed and screened in the labo-
ratory of BrianSeed, Department of Molecular Medicine, Massachusetts General Hospital,
Boston, MA.
Recovery and Characterization ofcDNA Clones.
￿
Screening for positive clones by transient ex-
pression and rescue was carried out as described (20). After three rounds of expression and
panning in COS cells, on retransformation ofE. coli, DNA was prepared from single colonies
and retransfected into COS cells. Methods for transfection, immunoprecipitation, and RNA
and DNA blot hybridization were all as previously described (20), except that probes were
made by random priming on purified inserts. DNA sequencingwas carried out by the super-
coil method (31).
Treatment of COS Cells with Phosphatidylinositol-speck Phospholipase C (PI-PLC).
￿
COS cells
(107) transfected with a cDNA encoding CD59 antigen (YTH 53.1/1) were taken into PBS/1
mM EDTA and iodinated with 1251 and Enzymobeads (Bio-Rad Laboratories, Richmond,
CA), according to the manufacturer's instructions. The cell suspension in isotonic sucrose
was then divided into two equal aliquots of 50 tal, and incubated for 30 min at 37°C with
or without 10 U of PI-PLC. (Bacillus thuringiensis). Cells and supernatant were separated by
centrifugation, and the cells were lysed in 100 mM Tris, pH 8.0/200 mM NaCl/1 mM EI7TA/1 %
NP-40. Each fraction was incubated with 1 P,g YTH 53.1 IgG overnight at 4°C, after which
time 50 I1 goat anti-rat Ig coupled to agarose (Sigma Chemical Co.) was added, the samples
rotated at 4°C for 2 h, then washed by spinning through 30% sucrose in lysis buffer. Antigen
was eluted from the agarose by boiling the beads for 2 min in 20 'al reducing buffer, then
analyzed by SDS-PAGE followed by autoradiography.
Results
Cell Distribution of YTH 53.1.
￿
The reactivity of YTH 53 .1 with a variety of fresh
cells and lines was measured by immunofluorescence. The antigen is broadly dis-
tributed and most target cells were positive to some degree (Table 1). This experi-
ment was part ofa much larger study in which 80 othermAbs were included, reacting
with a variety of defined and novel cell surface antigens (32). Cluster analysis within
the panel revealed no other similar antibodies, and comparison with data from the
3rd Leucocyte Workshop (33) likewise did not reveal any obvious candidates that
might identify the same target. However, YTH 53.1 was included in the nonlineage
panel of the 4th Leucocyte Workshop (antibody number N036) and binding ex-
periments on purified antigen indicated that it is similar to MEM-43 (antibody number
N705), (HoiejYi, V., personal communication).
Further experiments on cell distribution were carried out by measuring cell lysis
induced with YTH 53 .1 and human complement (Table 1). Relatively few mAbs
are lytic for human cells with homologous complement, a property that is as much
dependent on the target antigen as on the antibody isotype (34) and it was this prop-
erty that first led us to study the antibody.DAVIES ET AL .
￿
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TABLE I
Cell Distribution of YTH53.I by Immunofiuortscenct and
Complement-mediated Lysis
Cell type
￿
Immunoffuorescence
￿
Complement lysis
Lymphocytes
￿
Strong
￿
Weak
Granulocytes
￿
Strong
Platelets
￿
Weak
Erythrocytes
￿
Weak
￿
Strong
Activated T cells (3 d)
￿
Weak
Activated T cells (7 d)
￿
Weak
Reactivity with the cell lines is defined as negative (<5% positive cells above
negative control by immunoffuorescence or<5% 5'Cr release above control),
weak (20-70% positive cells by immunoffuorescence, not completely discrimi-
nated from control or 5-10% 51Cr release above control), or strong (>80%
positive cells, clearly discriminated from negative control or >50% 51Cr
release) .
" Reactivity with the cell line U937 varied from strong to negative, depending
upon the particular subline subjected to analysis.
Enhancement of Complement-mediated Lysis.
￿
During experiments designated to test
for synergistic lysis by pairs of antibodies against different epitopes on one antigen
(compare with reference 35) it was noted thatYTH 53.1 gave significantly enhanced
lysis whencombined with several other different specificities . Thisphenomenonwas
first demonstrated with intact Ig at sublytic or weakly lytic concentrations (data not
shown), but similar results could be obtained using F(ab')2 fragments . The F(ab')2
fragments alone were never lytic, even at a saturating concentration, which simplifies
subsequent interpretation . To illustrate the effect, different cell types havebeen used
(erythrocytes and lymphocytes), as well as a variety of partner antibodies (anti-A,
anti-B, anti-glycophorin, CAMPATH-1, CD7). We have not seen lysiswhen the partner
T cell lines
MOLT4 Strong Weak
HPBALL Strong
1301 Weak
551 Weak
JURKAT Strong
Karpas45 Strong
B cell lines
DAUDI Weak Negative
CLA4 Negative
HALM-1 Negative Negative
NALM-6 Negative
EBV lymphoblastoid Strong
Myeloid cell lines
U937 Variable' Negative
HL60 Strong Strong
Erythroid cell line
K562 Weak
Epithelial cell line
ESH92 Strong
Bladder carcinoma line
T24 Weak642
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antibody itselfwasnonlytic (CD7, data not shown), but when it was lytic thedegree
of lysis was enhanced in the presence of YTH 53 .1, i.e., the apparent titer of the
partner antibody was increased (Fig. 1).
Enhancement ofReactive Lysis Using YTH 53.1.
￿
In a reactive lysis system (1) where
sensitizing antibody is not used, human redcells are not easily lysed by human com-
plement in the fluid phase. However, human red cellsare more easily lysed by human
C56 and normal human serum, used as a source of C7-9, when they are incorpo-
rated into agarose. It is not clear why lysis of human red cells by homologous com-
plement occurs more readily in solid phase than in fluid phase; however, it would
appear that the phenomenon of homologous restriction is still operative in this system
sincelysisproceededmore quickly if normal humanserum was replaced with normal
rabbit serum (our unpublished observation). Therefore, this system was particu-
Antibody
6o
(A) Anti-A
(B) Anti-B
(C) Antiglycophorin
(D) CAMPATH-1
A
￿
and-A
Cells
Antibody dilution
￿
Antibody dilution
FIGURE 1.
￿
Enhancement of complement-mediated cell lysis by F(ab')2 fragments of YTH 53.1.
Each incubation contained 50 pl of F(ab')2 fragments (50 ug/ml) (" ) or medium (O), 50 Al of
partner antibody or medium (control), 50 pl of SICr-labeled cells, and 50 ul of complement.
Group A erythrocytes
Group B erythrocytes
Group O erythrocytes
Blood lymphocytes
e
￿
ant-e
Complement
A serum, diluted 1:4
B serum, diluted 1 :4
A serum, diluted 1 :4
A serum, diluted 1 :2.5
0
1
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5 25 125 625 Con
Antibody ddubon
1
`t=:Q~0
5 25 125 625 Con
Antibody dilution
80
ant-gycophodn D CAMPATH-1
60
40
20
0
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larly suitable for testing the effects ofthemAbYTH 53 .1 upon reactive lysis ofhuman
red cells .
YTH 53.1 IgG in a well adjacent to the line of lysis caused an enhancement of
the lysis ofhuman red cells by human C56 and normal human serum (Fig . 2 a),
whereas no enhancementwas observed when guinea pigred cellswere used in place
of human red cells (Fig . 2 b) . Plates were poured in PBS/10 mM EDTA in order
to inhibit activation of early complement components in the whole serum used, and
rat monoclonal anti-glycophorinA IgG, used as a control, had no effect upon the
lysis of human red cells by homologous complement (Fig . 2 a) . This antibody is
of the same subclass asYTH 53 .1 and in normally lytic for human red cells . The
ability ofYTH 53 .1 to enhance reactive lysis ofhuman red cells was also evident
when sheep C56 was used insteadofhuman C56, butwas notobservedwhen normal
human serumwas replaced with normal rabbit serum (Fig . 3) . In Fig . 3, the marked
difference between the degree of lysis ofhuman red cells caused by rabbit serum
andbyhuman serum is duenot only to the phenomenon of homologous restriction,
but also to some extent to the fact that sheep C56 reacts more readily with rabbit
complement than it does with human complement . Thesedata collectively indicate
that YTH 53 .1 reacts with and neutralizes the activity ofa molecule that restricts
lysis by homologous complement at a stage subsequent to the generation ofC56 .
Purification ofCD59 Antigen .
￿
The protein recognized byYTH 53 .1 was purified
from solubilizedhuman erythrocyte membranesby affinity chromatography, as de-
scribed . Material eluted from the column was run on a 10-20% gradient gel, and
silver staining revealed a single band ofapproximate molecularmass of 19kD under
both reducing and nonreducing conditions (Fig . 4). When the same column was
FIGURE 2 .
￿
Enhancementof reactive lysisbyYTH.53.1 . Reactive lysis plates were prepared as
described in Materials and Methods . (a) Human erythrocytes incubated for 22 h at room tem-
perature. (b) Negative control. Guinea pig erythrocytes incubated for 5 h at room temperature.
The center wells contained 10 p,l of human C56 (2.2 mg/ml) . The contents of the outer wells
(10 Al) were as follows : (1) normal human serum ; (2) YTH 53 .1 IgG prepared from ascites (4
mg/ml); (3)YTH 89.1 (anti-glycophorin) IgGprepared from ascites(1 mg/ml) ; (4) normal human
serum ; (5) YTH 53 .1 IgG prepared from ascites (1 mg/ml) ; (6) YTH 89 .1 (anti-glycophorin)
IgG prepared from ascites (4 mg/ml) .644
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FIGURE 3 .
￿
Comparison of the effects ofYTH
53 .1 upon lysis mediated by sera from different
species. The reactive lysis plate containedhuman
erythrocytes andwas incubated at room temper-
ature for 5 h . The center well contained 10 Pl
sheep C56 . The contents of the outer wells (10
141) were as follows : (1) normal humanserum; (2)
YTH53 .1 IgGprepared from ascites (4 mg/ml) ;
(3) YTH 89 .1 (anti-glycophorin) IgG prepared
from ascites (1 mg/ml); (4) normal rabbit serum ;
(5) YTH 53 .1 IgG prepared from ascites (1
mg/ml) ; (6)YTH89 .1 IgG (anti-glycophorin) IgG
prepared from ascites (4 mg/ml) .
used to extract protein from concentrated human urine, a slightly larger band of
-20 kD was observed by SDS PAGE (Fig . 4), with a second, lightly stained band
at -45 kD occurringin some preparations (Fig . 5) . On two occasions, a larger pro-
tein with approximate molecular mass of 80 kD underreducing conditions was no-
ticed, once in theabsenceofthe usual 20-kDprotein; the significance ofthis compo-
nent and its relationship to the 20-kD protein are currently under investigation .
Effects ofa Polyclonal Antiserum against CD59 Antigen on Reactive Lysis .
￿
Apolyclonal
antiserum raised againsturine-derivedCD59 antigendetectedCD59 antigenin urine
in Ouchterlony tests . IgG prepared from this antiserum also enhanced the reactive
lysisofhumanred cellsby humancomplement (Fig. 6) . IgG prepared from preinocu-
lation serum taken from the same animal was without effect .
Relationship ofCD59 Antigen toMIP .
￿
MIP is a 55/65-kD protein found inhuman
serum and on human red cell membranes, with the capacity to bind C8 and C9
(14) . In these respects, it is highly similar to HRF/C8bp (7, 13) . The relationship
FIGURE 4 .
￿
SDS-PAGE ofurine- andmembrane-derived CD59 antigen .
20,ul samples ofpooled fractions eluted from theYTH 53 .1 affinity column
were heated at 100°C in 20 p,l of reducing buffer before loading onto a
10-20% acrylamide gel. Protein bands were detected by silver staining .
(Lane 1) Urine-derivedCD59 antigen; (lane 2) membrane-derived CD59
antigen ; (lane 3) urine- and membrane-derived CD59 antigens .DAVIES ET AL .
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FIGURE 5 . SDS-PAGE of fractions
eluted from theYTH 53 .1 affinity col-
umn. 20-pl samples from 0.5-ml frac-
tions were heated at 100°C in 20 pl
nonreducing buffer before loadingonto
a 10-20% gradient gel . Bands were
visualized by Coomassie stain. (Lane 1)
Molecular weight standards . (Lane 2)
10 pgYTH 53 .1 IgG used to prepare
the column. (Lanes3-8) Samples from
a series of alternate fractions collected
after commencement of elution with
0.1 M acetic acid, pH 3 .0/0 .2% NP40.
of CD59 antigen to MIP was investigated in order to rule out the possibility that
CD59 antigen might be a truncated version of this larger protein. Comparativedouble
diffusion on Ouchterlony plates usingpolyclonal antisera against CD59 antigen and
against MIP, with concentrated urine as an antigen source, failed to demonstrate
a relationship betweenCD59 antigen and MIP, as theprecipitation lines found cross
and therefore show nonidentity (data not shown) .
Isolation ofcDNA Clones Encoding Antigenic Determinants Recognized by the mAb YTH
53.1 . cDNA libraries prepared as described were introduced into COS cells by
spheroplast fusion . COS cells expressing cDNAs encoding the protein of interest
were detected by panning (20) using YTH 53.1 . Hirt supernatant DNA prepared
from the positive cells was transformed intoE . coli, and plasmidDNA isolated from
eight of the colonies was transfected into COS cells for analysis by immunofluores-
FIGURE 6 .
￿
Enhancement of reactive lysis ofhu-
manerythrocytes by rabbit polyclonal antibody
against CD59 antigen . The plate was prepared
as described in Materials andMethods, and in-
cubated at room temperature for 5h . The center
well contained 10 Al ofhuman C56 (2.2 mg/ml) .
The contents of the outer wells (10 pl) were as
follows : (1) normal humanserum; (2) polyclonal
anti-CD59 antigenIgG prepared from serum (3
mg/ml); (3) nonimmuneIgG prepared from pre-
inoculation serum (1 mg/ml) ; (4) normal human
serum ; (5) polyclonal anti-CD59 antigen IgG pre-
pared from serum (1 mg/ml); (6)nonimmuneIgG
prepared from preincubation serum (3 mg/ml).646
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wcence. Sixofthese eight miniprep sampleswere positive; five ofthesesix clones (YTH
53.1/1,3,4,5, and 6) were pursued further. Restriction enzyme analysis revealed that
YTH 53.1/1 and YTH 53.1/5 are probably identical, as are YTH 53.1/3 and YTH
53.1/4.
cDNA SequenceAnalysis.
￿
The clones YTH 53.1/1,3, and 6 were sequenced as de-
scribed. The sequence data show that YTH 53.1/1 and YTH 53.1/5 are -1,154 by
in length and have poly(A) tails (A14), YTH 53.1/6 is 427 bp, YTH 53.1/3 547 bp,
and YTH 53.1/4 530 by in length. YTH 53.1/3, which also has a poly(A) tail
(AnCA8), utilizes a polyadenylation signal at 509 by that isignored in YTH 53.1/1
and YTH 53.1/5. Both YTH 53.1/4 and YTH 53.1/6 lack a poly(A) tail (Fig. 7).
NH2-terminal Sequence Analysis ofCD59 Antigen.
￿
Automated sequence analysis was
carried out first on a sample of urine-derived CD59 antigen and subsequently on
CGCAGAAGCGGCTCGAGGCTGGAAGAGGATCCTGGGCGCCGCCAGGTTCTGTGGACAATC
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250 260 270 280 290 300
55
￿
60
￿
65
￿
70
R E N E L T Y Y C C K K D L C N F N E Q
AGGGAAAATGAGCTAACGTACTACTGCTGCAAGAAGGACCTGTGTAACTTTAACGAACAG
310 320 330 340 350 360
75
￿
80
￿
85
￿
90
L E N G G T S L S E K T V L L L V T P F
CTTGAAAATGGTGGGACATCCTTATCAGAGAAAACAGTTCTTCTGCTGGTGACTCCATTT
370 380 390 400 410 420
95
￿
100 103
L A A A N S L H P
￿
ya
CTGGCAGCAGCCTGGAGCCTTCATCCCTAAGTCAACACCAGGAGAGCTTCTCCCAAACTC
430 440 450 460 470 480
CCCGTTCCTGCGTAGTCCGCTTTCTCTTGCTGCCACATTCTAAAGGCTTGATATTTTCCA
490 500 510 520 530 540
AATGGATCCTGTTGGGAAA TC '1"1'AGCTTGAGCAAC
b
L CTAAGATAGA000GT
550 560 570 580 590 600
CTGGGAGACTTTGAAGACCAGTCCTGCCCGCAGGGAAGCCCCACTTGAAGGAAC,AAGTCT
610 620 630 640 650 660
AAGAGTGAAGTAGGTGTGACTTGAACTAGATTGCATGCTTCCTCCTTTGCTCTTGGGAAG
670 680 690 700 710 720
ACCAGCTTTGCAGTGACAGCTTGAGTGGGTTCTCTGCAGCCCTCAGATTATTTTTCCTCT
730 740 750 760 770 780
GGCTCCTTGGATGTAGTCAGTTAGCATCATTAGTACATCTTTGGAGGGTGGGGCAGGAGT
790 Boo 810 820 830 840
ATAT'GAGCATCCTCTCTCACATGGAACGCTTTCATAAACTTCAGGGATCCCGTGTTGCCA
850 860 870 880 890 900
TGGAGGCATGCCAAATGTTCCATATGTGGGTGTCAGTCAGGGACAACAAGATCCTTAATG
910 920 930 940 950 960
CAGAGCTAGAGGACTTCTGGCAGGGAAGTGGGGAAGTGTTCCAGATTCCAGATAGCAGGG
970 980 990 1000 1010 1020
CATGAAAACTTAGAGAGGTACAAGTGGCTGAAAATCGAGTTTTTCCTCTGTCTTT~T
1030 1040 1050 1060 1070
!MrATGGGCTTTGTTATCTTCCACTGGAAAAGTGTAATAGCATACATCAATGGTGTGTT
1090 1100 1110 1120
1
130 1140
1150
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FIGURE 8. The nucleotide sequence
shown is that of the longest clone, YTH
53.1/1, and encodes a precursor polypep-
tide of 128 amino acids. NH2-terminal se-
quence analysisofCD59 antigen purified
both from urine and erythrocyte mem-
branes indicates the position of the NH2
terminus ofthe processed protein (Leu-1).
The probable initiation codon is met -25,
with residues -25 to -1 representing a
signal peptide. Residues underlined were
determined by sequence analysis of the
urine protein. Sequence analysis of the
membrane protein (which was s-carboxy-
methylated before sequencing) confirmed
residues 2-35, and also identified cysteine
residues 3, 6, 13, 19, and 26. No signal was
detected for either protein at position 18.
a, 3' end of clone YTH 53.1/6; b, 3' end
of clones YTH 53.1/4 and YTH 53 .1/3
(with poly(A)` tail); c, 3' end of clones
YTH 53.1/1 and YTH 53.1/5; i, boxed
nucleotides indicate polyadenylation signal
utilized in clone YTH 53.1/3; ii, potential
polyadenylation site utilized in clones
YTH 53.1/1 and YTH 53.1/5.648
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Position
LY-6K
CD59
1 10 10 30 40 50 60
LS:YOCYGVPFSTSCP-SITCPYPDGVCVTp6AAVIVCSQTRKVKN!LCLPI--CPPNIS
LOCYNC-PNPT-ADCKTAVNCSSDFDACLITRAGLOV--------YNKCNKFSRCNFN--
Position 61 70
￿
80
￿
90 100 110
LY-66 SNEILGTKVNVKTS000OSDLCN--AAVPNGGSTNTNAGVLLF6LSSVLLOTLL--
CD59 DVTTRLRSNBLTYYCCKKDLCNFNSOLENGGTSLSSKTVLLLVTPFiAAANSLRP
FIGURE 9 .
￿
Alignment ofCD59 antigen
andmurine LY6E antigen amino-acid se-
quences . Numbering refers to the position
in the aligned sequences, and does not
therefore correspond with the residue
number ofeither sequence. Residues con-
served in both sequences are indicated by
an asterisk .
a sample of the membrane-derived protein that had been reduced and alkylated .
Sequence data for the two samples are shown in Fig . 8, in comparison with the se-
quence deduced from the cDNA isolated as described above. The urine- and
membrane-derived CD59 antigens had identical NH2-terminal sequences ; these
were in agreement with the residues predicted by the cDNA sequence for positions
1-43 . This indicates that the probable initiation codon is at met -25, and that residues-
25 to -1 represent a signal peptide . This sequence comparison also demonstrates
that the predicted residue at position 18, asn-18, occurs within a glycosylation signal
sequence (N-C-S) . The lack ofa detectable residue at this position in the protein
sequence indicates that it is N-glycosylated in the mature protein . In contrast, while
asn-8 also occurs within a potential glycosylation site (N-PT), it is recovered in ap-
propriate yield during sequence analysis ofboth urine- andmembrane-derived pro-
teins, indicating that it is not glycosylated to any significant degree inCD59 antigen.
Searches of sequence databases did not demonstrate a high degree of sequence
homology ofCD59 antigen with other proteins. However, thebestmatch (26% overall
identity) was to amurine lymphoid cell protein, the LY6E antigen (36) . The aligned
sequences are shown in Fig. 9.
RNA andDNA Blot Analyses.
￿
RNA blot analysis on a range ofhuman cell lines
revealed four species ofRNA at -600 bp, 1.2 kb, 1.9 kb, and 2.2 kb present in varying
amounts in different cells (data not shown) . The lower bands at 600 by and 1.2 kb
probably correspond to the clones YTH 53 .1/3 (547 bp) and YTH 53 .1/1 and /5
(1,154 bp), respectively ; the larger bands do not correspond to any of the cDNAs
so far isolated . Southern blot analysis on human placental genomic DNA revealed
a simple pattern consistent with a single gene copy (data not shown) .
Release ofCD59Antigenfrom the Surface ofCOS Cells byPI-PLC.
￿
Incubation ofCOS
cells transfectedwith thecDNA encodingCD59 antigenwith PI-PLC fromB . thurin-
FIGURE 10 .
￿
Immunoprecipitation ofCD59 antigen from the su-
pernatant or lysate of radioiodinated COS cells after incubation
at 37GC for 30 min in the presence (lanes 3and 4) orabsence (lanes
1 and 2) of10 UofPI-PLC (B . thuringttmsis). (Lanes Iand 3) Samples
of cell supernatant after incubation. (Lanes 2 and 4) Samples of
cell lysate after incubation. The mobilities of molecular weight
markers are as indicated .DAVIES ET AL.
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giensis caused the release of almost all of the antigen from the cell surface into the
supernatant (Fig. 10). Cellsincubated in parallel butwithoutPI-PLC retained their
surface expression of CD59 antigen. These data show that CD59 antigen utilises
a glycolipid anchor for attachment to the cell surface.
Discussion
We have reported herein the identification of a 20-kD membrane protein that is
capable of inhibiting complement-mediated lysis. This protein was detected on a
broad range of cell types using the mAb YTH 53.1, which was designated CD59
at the 4th Leucocyte Workshop (19). In this present study, YTH 53.1 was found
to enhance the lysis of human erythrocytes by human complement in two separate
hemolytic assay systems, thereby indicating a role for CD59 antigen in protecting
againstcomplement-mediated lysis. Thefact that YTH 53.1 enhanced lysisin areactive
lysis system, which uses pre-activated C56 complex, indicatesthat protection against
lysis mediated by CD59 antigentakeseffect in the later stages of complement activa-
tion, during assembly of the MAC. Moreover, comparative assays using different
species of C56 and of serum used as a source of C7-9 revealed that the inhibitory
capacity of CD59 antigen is effective only against homologous complement.
The antibody YTH 53 .1 was used both to purify CD59 antigen by affinity chro-
matography and to isolate the corresponding cDNA from a human T cell library.
Antigen extracted from human erythrocyte stroma or from human urine has an
approximate molecular mass of 19-20 kD, while the isolated cDNA encodes a pro-
tein of ti 11.5 kD molecular mass. This discrepancy between predicted size and ap-
parent molecular mass asjudged by SDS-PAGE may partly be dueto N-glycosylation
of the asparagine residue at position 18, as suggested by the lack of a signal at this
residue during sequencing ofthe purified protein. Furthermore, theposttranslational
addition of a glycolipid anchor may causethe molecular mass of the mature protein
to be increased, though it is not possible to calculate exactlyhowmuch this modification
might change the molecular mass withoutknowing how much of the protein COOH
terminus is removed during the process.
RNA blot analyses on a range of human cell lines revealed the existence of longer
mRNA transcripts that do not correspond to any of the isolated cDNAs, presum-
ably because they are either untranslated or encode polypeptides that are not ex-
pressed on the cell surface and therefore would not be detected by the panning pro-
cedure. Polyacrylamide gel electrophoretic analysis ofaffinity-purified CD59 antigen
from human urine also revealed a slightly larger component (45 kD) in some prepa-
rations, and on two occasions YTH 53.1 in solid phase extracted an 80-kD compo-
nent from human urine. The reason why an 80-kD component was observed only
in two instances during repeated preparations of CD59 from human urine, and on
one of those occasions in the absence of the usual 20-kD protein, is not clear, and
currentlyunder investigation. Some preliminary resultsindicate that the polyclonal
anti-CD59 antiserum recognizes an 80-kD component in urine and serum by im-
munoblotting (data notshown), suggesting that this component canbe detected directly
by antibody against CD59 antigen, rather than indirectly by means of an associa-
tion with CD59 antigen. It is not knownwhetherthese larger bandsrepresent larger
versions of the CD59 antigen or are caused by the crossreaction of YTH 53 .1 with
related proteins in the urine.650
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Severalothermembrane proteins have been described that protect against thelytic
action of the MAC. These include homologous restriction factor (HRF)/C8 by (7,
13) and MIP (14). Since HRF/C8bp has an approximate molecular mass of 70 kD,
CD59 antigen is clearly distinguishable from HRF/C8 by by virtue of its size: both
protein and cloning data indicate that CD59 antigen is a much smaller molecule,
though its relationship to the larger bands occasionally associated with it remains
obscure. As there are no sequence data available for HRF/C8bp, the distinction be-
tween HRF/C8bp and CD59 antigen cannot yet be confirmedby direct comparison
of the primary amino acid sequences. With a molecular mass of 55/65 kD, MIP
has a size approachingthat ofHRF/C8bp (Watts, M. J., and B. P Morgan, personal
communication). The relationship of MIP to HRF/C8bp is unclear at present, but
Ouchterlony tests using polyclonal antisera to CD59 antigen and to MIP have es-
tablished that the native proteins do not share epitopes. Recently, Sugita et al. (37)
reported the isolation from human erythrocyte stroma of an 18-kD protein capable
of inhibiting the reactive lysis of guinea pig cells by human complement . It seems
likely that this protein, named P-18, is the same as CD59 antigen, though as yet
no structural data for P-18 are available for comparison.
An 18-25-kD glycoprotein broadly expressed on human leucocytes and erythro-
cyteshas recently been identified by ~tefanovaet al. (18) usingtheir mAb MEM-43 .
This antibody was placed in a cluster(CD59) with YTH 53.1 at the 4th Leucocyte
Workshop, and comparison of the NH2-terminal amino acid sequence of the MEM-
43 antigen (18) with the sequence for the 20-kD protein described here indicates
that the two antibodies do in fact recognize the same molecule. ~tefanova et al., (18)
also noticed the sequence similarity, at the NH2 terminus, between the glycopro-
tein isolated using MEM-43 and the LY6 antigens. The overall degree ofhomology
between the murine LY6E and CD59 antigens is not high (26% identity). Two fur-
ther LY6 sequences have recently been published. One, Ly-6A, has only two differ-
ences to LY6-E (38, 39). The second, LY6-C, while only 62% homologous to LY6-E
(40), has a similar (26%) degree of homology to CD59. In addition, both LY6 and
CD59 antigens are of similar length (108 or 105 vs. 103 residues), both contain 10
cysteine residues, and interestingly, both are expressed as PI-linked cell membrane
proteins. Taken together these data are strong evidence for a distant evolutionary
relationship between the proteins. Both CD59 and LY6 antigens are broadly ex-
pressed on a variety of cell types. However, while our data demonstrate that CD59
antigen plays a role in protection of the host cell against lysis by the MAC of homol-
ogous complement, LY-6 antigens have been implicated in augmentation of response
to TCR stimulation. Although a human homologue of LY6 has not yet been de-
scribed, it therefore appears unlikely that the relationship of CD59 and LY6 an-
tigens extends beyond a structural similarity. A possible evolutionary relationship
between a squid glycoprotein (SGP2) and LY6 antigens has also been suggested(41).
These and other homologies are discussed more fully elsewhere (Harrison, R. A.,
D. L. Simmons, A. Davies, G. Hale, P J. Lachmann, and H. Waldmann, manu-
script in preparation).
Interestingly, an 80-kD component has also been associated with the MEM-43
antigen: immunoprecipitation from HPB-ALL cell lysatesusing MEM-43 detected
an 80-kDband as well as the usual band within the 18-25-kDaregion (18) . However,
this 80-kD band component was never observed in preparations of the MEM-43DAVIES ET AL.
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antigenobtained by affinity chromatography, contrary to ourexperience during routine
preparation of CD59 antigen from urine using the same technique.
The removal by PI-PLC of CD59 antigen expressed on the surface of COS cells
suggests that it is linked to the cell surface by means of a glycolipid anchor. This
was also demonstrated by ~tefanova et al. (18) using MEM-43 to measure the re-
lease of CD59 antigen from the surface of PBMC by PI-PLC, and was confirmed
by workshop studies (19). In view of this, it can be expected that CD59 antigen will
be absent from the surface of affected erythrocytes in patients suffering from parox-
ysmal nocturnalhemoglobinuria (PNH), since such cells lack proteins that use the
glycolipid anchor, for example, DAF and HRF/C8bp (42-44). An additional deficiency
ofCD59 antigenin PNH wouldbe particularly significant, sinceCD59 antigen may
act in synergy with HRF/C8bp to protect cells from complement-mediated lysis.
Complement-mediated cell lysis is used as a means of purging the bone marrow
ofunwanted cellsin preparationfortransplantation. The useofhuman complement
for this purpose is not always practical because of the reduced efficiency with which
complement lyseshomologous cells; this canbe aparticular problem if the antibody
that needs to be used to sensitize the target cell is not itself very lytic. However, the
use of human complement is, in principle, preferable to that of rabbit complement
because of the variable nonspecific toxicity that is associated with the latter (45),
so a means ofaugmenting the lytic potential of human complement against autolo-
gous cells would be useful. In this respect, antibodies that can inhibit the effect of
complement regulatory proteins may be of benefit therapeutically, to increase the
susceptibility of target cells to lysis by autologous complement. YTH 53.1 may be
one such antibody.
It is hoped that further investigations using purified CD59, as well as antibodies
directed against it, will help to reveal the mechanism by which CD59 inhibits
complement-mediated lysis.
Summary
A novel cell surface antigen has been identified on awide range of lymphoid cells
and erythrocytes. A mAb YTH 53.1 (CD59) againstthis antigen enhanced the lysis
of human red cells and lymphocytes by homologous complement. Studies of reac-
tive lysisusingdifferentspeciesofC56, and ofwhole serum used as asource ofC7-9,
indicated that the inhibitory activity of the CD59 antigen is directed towards the
homologous membrane attack complex. CD59 antigen was purified from human
urine and erythrocyte stroma by affinity chromatography usingthe mAb YTH 53 .1
immobilized on Sepharose, and, following transient expression of a human T cell
cDNA library in COScells, thecorresponding cDNA also identified using the anti-
body. It was found that the CD59 antigen is a small protein (N20 kD as judged by
SDS-PAGE, 11.5 kD predicted from the isolated cDNA) sometimes associated with
larger components (45 and80 kD) in urine. The sequence ofCD59 antigen is unlike
that ofothercomplement components or regulatory proteins, but shows 26% iden-
tity with that of the murine LY6 antigen. CD59 antigen was released from the sur-
face of transfected COS cells by phosphatidylinositol-specific phospholipase C, demon-
strating that it is attached to the cell membrane by means of a glycolipid anchor;
it is thereforelikely to be absent from the surface ofaffected erythrocytes in the dis-
ease paroxysmal nocturnal hemoglobinuria.652
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